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https://doi.org/10.1016/j.celrep.2020.108552SUMMARYExtracellular RNAs present in biofluids have emerged as potential biomarkers for disease. Where most
studies focus on blood-derived fluids, other biofluids may be more informative. We present an atlas of
messenger, circular, and small RNA transcriptomes of a comprehensive collection of 20 human biofluids.
By means of synthetic spike-in controls, we compare RNA content across biofluids, revealing a 10,000-
fold difference in concentration. The circular RNA fraction is increased inmost biofluids compared to tissues.
Each biofluid transcriptome is enriched for RNA molecules derived from specific tissues and cell types. Our
atlas enables an informed selection of the most relevant biofluid to monitor particular diseases. To verify the
biomarker potential in these biofluids, four validation cohorts representing a broad spectrum of diseases
were profiled, revealing numerous differential RNAs between case and control subjects. Spike-normalized
data are publicly available in the R2 web portal for further exploration.INTRODUCTION
Extracellular RNAs (exRNAs) in blood and other biofluids are
emerging as potential biomarkers for a wide range of diseases
(Freedman et al., 2016; Godoy et al., 2018; Max et al., 2018; Wei-Ce
This is an open access article under the CC BY-Nland et al., 2012; Yuan et al., 2016). These so-called liquid bi-
opsies may offer a non-invasive alternative to tissue biopsies
for both diagnosis and treatment response monitoring.
Previous studies have extensively profiled the small RNA




OPEN ACCESSthe small RNA content among different biofluids (El-Mogy et al.,
2018; Fehlmann et al., 2016; Ferrero et al., 2017; Freedman
et al., 2016; Godoy et al., 2018; Max et al., 2018; Murillo
et al., 2019; Srinivasan et al., 2019; Umu et al., 2018; Weiland
et al., 2012; Yeri et al., 2017; Yuan et al., 2016). These efforts
were gathered by the NIH Extracellular RNA Communication
Consortium in the exRNA Atlas Resource (https://exrna-atlas.
org) (Murillo et al., 2019). Besides microRNAs (miRNAs), the
most studied small RNA biotype in biofluids, other small
RNAs, such as piwi-interacting RNAs (piRNAs), small nuclear
RNAs (snRNAs), small nucleolar RNAs (snoRNAs), ribosomal
RNAs (rRNAs), transfer RNA (tRNA) fragments, and Y-RNAs
have also been identified (El-Mogy et al., 2018; Ferrero et al.,
2017; Godoy et al., 2018; Srinivasan et al., 2019; Weber,
2017; Yeri et al., 2017). Weber (2017) was the first to compare
the miRNA content in 12 different human biofluids (pooled sam-
ples of plasma, saliva, tears, urine, amniotic fluid, colostrum,
breast milk, bronchial lavage fluid, cerebrospinal fluid [CSF],
peritoneal fluid, pleural fluid, and seminal plasma) using
quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) of selected miRNAs. Large variations in RNA con-
centration were observed among the different biofluids, with
the highest small RNA concentrations measured in breast
milk and seminal fluid. Since the advent of small RNA
sequencing, other small RNA biotypes were characterized in
various biofluids, such as plasma, serum, stool, urine, amniotic
fluid, bronchial lavage fluid, bile, CSF, saliva, seminal plasma,
and ovarian follicle fluid (El-Mogy et al., 2018; Ferrero et al.,
2017; Godoy et al., 2018; Srinivasan et al., 2019).The distribu-
tion of small RNA biotypes clearly varies across these biofluids,
with a high abundance of piRNAs and tRNAs reported in urine
and a high abundance of Y-RNAs in plasma (El-Mogy et al.,
2018; Ferrero et al., 2017; Yeri et al., 2017). Also non-human
RNA sequences, mapping to bacterial genomes, were reported
in plasma, urine, and saliva (Yeri et al., 2017).
A systematic RNA-sequencing analysis of biofluids to
explore the messenger RNAs (mRNAs) and circular RNA
(circRNA) transcriptome is challenging due to low RNA con-
centration and RNA fragmentation in biofluids. As such,
most studies have explored the abundance of individual
mRNAs in one specific biofluid by qRT-PCR (Herring et al.,
2018; Maker et al., 2019; Marzioni et al., 2015; Oreo et al.,
2014; Tian et al., 2016; Welch et al., 2016). circRNAs have
been reported in saliva (Bahn et al., 2015), semen (Liu et al.,
2019), blood (Li et al., 2018a), and urine (Kölling et al., 2019;
Vo et al., 2019). Recently, the mRNA content of plasma and
serum has been investigated using dedicated sequencing ap-
proaches such as phospho-RNA-seq, small input liquid vol-
ume extracellular RNA sequencing (SILVER-seq), and the
SMARTer Stranded Total RNA-Seq Kit method (Everaert
et al., 2019; Giraldez et al., 2019; Metzenmacher et al.,
2020; Zhou et al., 2019). Studies comparing the small RNA,
mRNA, and circRNA content in a wide range of human bio-
fluids are currently lacking and are essential to explore the
biomarker potential of exRNAs.
The goal of the Human Biofluid RNA Atlas is to define the
extracellular transcriptome across a wide range of human bio-
fluids (amniotic fluid, aqueous humor, ascites, bile, bronchial2 Cell Reports 33, 108552, December 29, 2020lavage fluid, breast milk, CSF, colostrum, gastric fluid, pancre-
atic cyst fluid, plasma, saliva, seminal fluid, serum, sputum,
stool, synovial fluid, sweat, tear fluid, and urine) and to assess
biomarker potential in selected case-control cohorts. We used
small RNA sequencing to quantify different small RNA species
and present a dedicated mRNA capture sequencing workflow
to simultaneously quantify mRNAs and circRNAs.
In the first phase of our study, small RNA sequencing and
mRNA capture sequencing were performed in a discovery
cohort of 20 different biofluids (Figure 1). The goal of this phase
was to assess the technical feasibility of the methodology and to
generate a comprehensive set of mRNAs, circRNAs, and small
RNAs in which the contributing tissues and cell types per biofluid
were assessed.
In the second phase of our study, we aimed to investigate the
biological relevance of exRNAs in various biofluids. Therefore,
mRNA capture sequencing was applied to four different case/
control cohorts, each consisting of 16–24 samples (Figure 1).
These samples included sputum samples from 8 patients with
chronic obstructive pulmonary disease (COPD) versus 8 con-
trols, urine samples from 12 bladder cancer patients versus 12
controls, CSF samples from 12 glioblastoma patients versus
12 hydrocephalus patients and saliva samples from 12 diabetes
mellitus patients versus 12 controls.
The resulting catalog of extracellular transcriptomes of 185 hu-
man samples can guide researchers in the biomarker field to
investigate other biofluids besides the well-studied blood-
derived ones and is a first step to more dedicated mRNA and
circRNA profiling of biofluids in larger cohorts.
RESULTS
RNA Spike-In Controls Enable Process Control of the
RNA-Sequencing Workflow
Synthetic spike-in RNA sequences are crucial to control the pro-
cess from RNA isolation to RNA sequencing, especially when
working with challenging and low input material. We applied 4
different mixes of synthetic RNA spike-in controls (in total, 189
RNAs) as workflow processing and normalization controls that
enable direct comparison of the RNA profiles across the different
biofluids. Sequin and small RNA extraction control (RC) spikes
were added before RNA isolation, whereas External RNA Con-
trols Consortium (ERCC) spikes and small RNA library prepara-
tion (LP) spikes were added to the RNA eluate before genomic
DNA (gDNA) removal (Figure 1). Of note, every spikemix consists
of multiple RNA molecules of different lengths over a wide con-
centration range. Detailed information is provided in Methods
S1. Besides normalization, the spike-in controls enabled quality
control of the RNA extraction and library preparation steps in the
workflow and relative quantification of the RNA yield and con-
centration across the different biofluids.
First, the correlation between the expected and the observed
relative quantities for all four spike mixes can be used to assess
quantitative linearity. In the discovery cohort, the expected and
the observed relative quantities for all four spike mixes were
well correlated (Pearson correlation coefficients range from
0.50 to 1.00 for Sequin spikes, 0.92 to 1.00 for ERCC spikes,
0.44 to 0.98 for RC spikes, and 0.40 to 0.96 for LP spikes). In
Figure 1. Study Flow Chart
In the discovery cohort, 20 different biofluids were collected in two donors or in a pool of 4–5 donors. In the case/control cohorts, selected biofluids (sputum, CSF,
urine, and saliva) were collected in 8–12 patients and an equal number of healthy controls. Both small RNA sequencing and mRNA capture sequencing were
performed in the discovery cohort. In the case/control cohorts, mRNA capture sequencing was performed. To compare the RNA content across the different
biofluids, the RC spikes and the Sequin spikes are used for normalization of small RNA and mRNA data, respectively. RC and Sequin spikes are added to the
biofluid before RNA isolation, and LP and ERCC spikes are added to the RNA eluate. BAL, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid; PRP, platelet-
rich plasma; PPP, platelet-poor plasma; PFP, platelet-free plasma.
Resource
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OPEN ACCESSsome biofluids (e.g., seminal plasma and tears), the sequencing
coverage of spikes was low, due to a high concentration of
endogenous RNA. Detailed information per sample is provided
in Figures S1 and S2.
The spike-in controls can also be used to assess the RNA
isolation efficiency. The Sequin/ERCC ratio and the RC/LP ratio
reflect the relative mRNA and miRNA isolation efficiencies,
respectively. A 170-fold difference and a 104-fold difference in
RNA isolation efficiency across the samples were observed
when assessing long and small RNAs, respectively (Figure S3).
These differences underline the challenges of working with
heterogenous samples and the importance of spike-in controls
for proper data normalization and cross-sample comparison of
results.Finally, the spikes can be utilized to normalize the endog-
enous RNA abundance data. In this study, we applied a bio-
fluid volume-based normalization by dividing the RNA reads
consumed by the endogenous transcripts by the sum of the
Sequin spikes for mRNA data and by the sum of the RC
spikes for small RNA data. The spike-normalized data repre-
sent relative abundance values of RNA molecules propor-
tional to the input volume. Of note, there is an inverse rela-
tionship between the number of spike-in RNA reads and
the number of endogenous RNA reads. As such, the ratio be-
tween the sum of the reads consumed by the endogenous
transcripts and the total number of spike-in reads is a rela-
tive measure for the RNA concentration of the various
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OPEN ACCESSHighly Variable mRNA and Small RNA Content among
Biofluids in the Discovery Cohort
Both small RNAs and mRNAs were quantified in each of the 20
biofluids in the discovery cohort. Mapping rates varied substan-
tially across the different biofluids (Figure 2A). In general, the
proportion of mapped reads was higher for the mRNA-cap-
ture-sequencing data (further referred to as mRNA data) than
for the small-RNA-sequencing data, in line with the fact that hu-
man mRNAs were enriched using biotinylated capture probes
during the library preparation. The fraction of mapped reads in
the mRNA data ranged from 16% in stool to 97% in seminal
plasma. Low mapping rates were observed in stool, in one of
the bile samples, and in saliva. Mapping rates for samples in
the case/control cohorts are in line with those of the discovery
cohort (Figure S4A). In the small-RNA-sequencing data, the pro-
portion of mapped reads ranged from ~7% in stool, saliva, and
CSF to 95% in platelet-rich plasma (PRP).
A 10,000-fold difference inmRNA and small RNA concentration
was observed between the lowest concentrated fluids (i.e.,
platelet-free plasma [PFP], urine, and CSF), and the highest
concentrated biofluids (i.e., tears, seminal plasma, and bile) (Fig-
ure 2B). The absolute mRNA concentration for each biofluid was
calculated based on the ERCC spikes and ranged from
0.002 ng/mL in aqueous humor to 33.973 ng/mL in bile (Table 1).
The generalizability of the difference in mRNA concentration be-
tween highly concentrated biofluids (seminal plasma) and lowly
concentrated biofluids (CSF) was confirmed in additional samples
(Figure S4B). In the discovery cohort, a 5,547-fold difference in
mRNA concentration is observed between seminal plasma and
CSF; in independent validation samples, a similarly large 19,851-
fold difference in mRNA concentration is observed between both
biofluids. In the discovery cohort, the mRNA and miRNA concen-
trations were significantly correlated across biofluids (Pearson
correlation coefficient = 0.76, p = 8.5e10; Figure 2D). Normalized
abundance levels of exRNAs were significantly correlated be-
tween biological replicates within each biofluid (Figure S5). The
median Pearson correlation coefficients of the mRNA and
the small RNA data were 0.84 and 0.92, respectively. Although
the mRNA and miRNA data were well correlated in most biofluids
(e.g., tears, colostrum, and saliva), correlation in other biofluids
(e.g., bile and pancreatic cyst fluid) was poor. These biofluids are
obtained with a more challenging collection method involving
echo-endoscopy, impacting the reproducibility of collection and
the correlation of the RNA content between biological replicates.
The likelihood of identifying RNA biomarkers in a given biofluid
will depend not only on its relative RNA concentration but also
on its RNA diversity, here approximated by the fraction of readFigure 2. mRNA and Small RNA Content Varies across the 20 Biofluids
(A) Percentage of the total read count mapping to the human transcriptome.
(B) Relative RNA concentration per biofluid; every dot represents the relative RNA
biofluid.
(C) The diversity of the RNA content expressed as fraction of read counts consum
unique reads are taken into account. Every dot represents the fraction in one sa
(D) Correlation between the small RNA and the mRNA relative concentrations.
coefficients are calculated on log10-transformed data.
(E) The fraction of reads that align to small RNA biotypes are shown per biofluid. O
BAL, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid; miRNA, microRNA; P
piRNAs, piwi-interacting RNAs; snRNAs, small nuclear RNAs; snoRNAs, small ncounts consumed by the top 10 most abundant mRNAs/miRNAs
(Figure 2C). In aqueous humor, the top 10 mRNAs represent up
to 70% of all reads, indicating that this fluid does not contain a
rich mRNA repertoire. In both PRP and platelet-poor plasma
(PPP), about 50% of all reads go to the top 10 mRNAs. Although
amniotic fluid has a median RNA concentration, this fluid seems
to contain a diverse mRNA profile, with only 7% of all reads going
to the top10mRNAs.When looking into themiRNAdata, the top10
miRNAs represent more than 90% of all reads in PFP, urine, and
serum. Bronchoalveolar lavage fluid (BAL) contains the most
diverse miRNA repertoire, with 57% of all reads going to the top
10miRNAs. Similar conclusionswith respect to biofluid exRNAdi-
versity can be drawn based on the number of miRNAs/mRNAs
representing 50% of the counts (Figure S6). RNA diversity is also
reflected by the number of detected exRNAs. The total number
of mRNAs and miRNAs detected with at least 4 counts in both
samples of the same biofluid ranged from 13,722 mRNAs in
pancreatic cyst fluid to 107 mRNAs in aqueous humor and from
231miRNAs in tears to 18miRNAs in stool (Table 1). The endoge-
nous RNA mass in nanograms present in 1 mL of each biofluid is
also provided in Table 1.
The Distribution of Small RNA Biotypes Varies across
the Different Biofluids
The distribution of small RNA biotypes shows distinct patterns
among the 20 different biofluids (Figure 2). The exceptionally
high percentage of miscellaneous RNAs (mainly, Y-RNAs)
observed in blood-derived fluids is in line with the findings of a
previous study (El-Mogy et al., 2018) and with the Y-RNA func-
tion in platelets. The fraction of reads mapping to miRNAs is
lower than 15% in all samples except PFP and one synovial fluid
sample. Tears, bile, and amniotic fluid have the highest fraction
of tRNA fragments, wherea saliva has the highest fraction of piR-
NAs. The rRNA fraction is higher than 15% in all samples except
tears, aqueous fluid, and the three plasma fractions. Themajority
of these readsmap to the 45S ribosomal RNA transcript. The un-
annotated read fraction contains mapped reads that could not
be attributed to one of the small RNA biotypes. These reads
most likely originate from fragmented longer RNAs, such as
mRNAs and long non-coding RNAs (Figure S7).
circRNAs Are Enriched in Biofluids compared to Tissues
circRNAs are produced from unspliced RNA through a process
called backsplicing, where a downstream 50 donor binds to an
upstream 30 acceptor. circRNAs are resistant to endogenous
exonucleases that target free 50 or 30 terminal ends. As a result,
circRNAs are highly stable and have extended half-livesconcentration in one sample, and every vertical mark indicates the mean per
ed by the top 10 most abundant mRNAs/miRNAs. Only genes with at least 4
mple, and every vertical mark indicates the mean percentage per biofluid.
The Pearson correlation coefficient is 0.76 (p = 8.5e1010). The correlation
nly mapped reads of the small-RNA-sequencing data are taken into account.
FP, platelet-free plasma; PPP, platelet-poor plasma; PRP, platelet-rich plasma;
ucleolar RNAs; tRNAs, transfer RNA.
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Bile 33.973 45 2,279
Seminal plasma 22.351 211 11,868
Synovial fluid 17.595 122 1,614
Colostrum 13.535 229 11,914
Breast milk 7.463 213 11,607
Tears 7.316 231 13,366
Pancreatic cyst fluid 1.643 129 13,722
Sputum 0.297 91 7,738
Amniotic fluid 0.206 119 10,531
Gastric fluid 0.181 21 9,288
Saliva 0.171 110 6,353
PRP 0.073 192 5,440
Ascites 0.056 75 5,578
BAL 0.053 126 3,565
PPP 0.026 113 4,548
Serum 0.023 122 4,152
Urine 0.016 41 2,094
PFP 0.013 95 2,699
Stool Calex 0.005 18 135
Stool 0.005 19 134
CSF 0.005 32 438
Sweat 0.002 45 410
Aqueous humor 0.002 20 107
For each biofluid, the meanmass of endogenous RNAs in nanograms de-
tected per 1 mL biofluid is provided. The number of mRNAs and miRNAs
with at least 4 unique read counts in both replicates is shown per biofluid.
BAL, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid; PFP,




OPEN ACCESScompared to linearmRNAs (Li et al., 2018b). circRNAs have been
reported to be present in numerous human tissues (Vo et al.,
2019) and in a few biofluids, such as saliva (Bahn et al., 2015),
blood (Memczak et al., 2015), semen (Liu et al., 2019) and urine
(Kölling et al., 2019; Vo et al., 2019). A direct comparison of the
circRNA read fraction between biofluids and tissues is currently
lacking in literature. We compared the circRNA fraction, for
genes that produce both linear and circular transcripts, identified
through mRNA capture sequencing of the 20 biofluids in this
study, with the circRNA fraction identified in mRNA capture
sequencing of 36 cancerous tissue types obtained from the
MiOncoCirc Database (Vo et al., 2019). Although more unique
backsplice junctions were identified in tissues compared to bio-
fluids, in line with the higher RNA concentration in tissues (Fig-
ure 3B), the circRNA read fraction is clearly higher in biofluid ex-
RNA compared to cellular RNA (Figure 3A). The median circRNA
read fraction in biofluids is 84.4%, which is significantly higher
than the median circRNA read fraction in tissues of 17.5%
(Mann-Whitney U test, two-sided, p = 5.36e12). For genes6 Cell Reports 33, 108552, December 29, 2020that produce both linear and circular transcripts, the stable
circRNAs are more abundant than the linear mRNAs in biofluids,
whereas it is the other way around in tissues.
We used two different methods to define the circRNA read
fraction (see ‘‘Circular RNA detection and circular/linear ratio
determination’’ in STARMethods; Figure S8): one based on indi-
vidual backsplice junctions (shown in Figure 3) and another
method based on backsplice junctions aggregated at gene level
(Figure S9). Both methods clearly point toward a substantial
enrichment of circRNAs in biofluids.
Assessment of Exogenous RNA in Human Biofluids
Two dedicated pipelines were used for the non-trivial assess-
ment of the presence of microbial or viral RNA in human biofluid
exRNA. Overall, the fraction of bacterial reads is higher in small-
RNA-sequencing data than in the mRNA data, in line with the un-
biased nature of small RNA sequencing and the targeted hybrid
capture enrichment using probes against human RNA during the
mRNA capture library preparation (Figure 4A). Stool (both collec-
tionmethods), sweat, saliva, and sputum are among the biofluids
with the highest fraction of bacterial RNA in both the small-RNA-
sequencing data and the mRNA data. The percentage of bacte-
rial reads in mRNA data and in small RNA data are significantly
correlated across biofluids (Pearson correlation coefficient =
0.78, p = 1.94e10).
Bacterial reads in aqueous humor and CSF, two fluids with
very low endogenous RNA content that were collected in a sterile
setting (and, thus, presumed to be sterile), most likely reflect
background contamination during the workflow (Heintz-Bu-
schart et al., 2018). To illustrate the biological relevance of the
bacterial signal, we looked into reads mapping to Campylo-
bacter concisus, a Gram-negative bacterium that is known to
primarily colonize the human oral cavity, with some strains trans-
located to the intestinal tract (Liu et al., 2018). We confirm the se-
lective presence of readsmapping toCampylobacter concisus in
saliva in both the small RNA and themRNA data (Figure 4B). In all
samples and for both the small RNA and themRNAdata, the per-
centage of the total reads that maps to viral transcriptomes is
less than 1%.
Assessment of the Tissues of Origin and Deconvolution
of Pancreatic Cyst Fluid
Gaining insights in tissue contribution to biofluid RNA profilesmay
guide the selection of the most appropriate biofluid to investigate
a given disease. To define tissues that specifically contribute RNA
molecules to individual biofluids, we explored the relationship be-
tween extracellular mRNA levels and tissue- or cell-type-specific
mRNA signatures. The heatmap in Figure 5A highlights the relative
contribution of tissues and cell types to a specific biofluid
compared to the other biofluids. More detailed results per biofluid
are shown in FigureS10. The results of this analysiswere validated
in an independent sample cohort for CSF, saliva, sputum, seminal
plasma, and urine (Figure S4C). As expected, prostate tissue RNA
markers are more abundant in urine and in seminal plasma than in
any other biofluid. Both sputum and saliva contain mRNAs spe-
cific for trachea and esophagus. In amniotic fluid, markers for
esophagus, small intestine, colon, and lung are more abundant
than for the other tissues and cell types, probably reflecting
A B
Figure 3. circRNAs Are Enriched in Biofluids compared to Tissues
(A) The circRNA fraction, calculated at the backsplice junction level, is plotted per sample and is higher in cell-free biofluid RNA than in tissue RNA. Only samples
with at least 100 backsplice junctions are plotted.
(B) The number of unique backsplice junctions per sample is higher in tissues compared to biofluids, in line with the higher input concentration of RNA into the
library prep.
AML, acute myeloid leukemia; BAL, bronchoalveolar lavage fluid; CSF, cerebrospinal fluid; HNSCC: head and neck squamous cell carcinoma; PFP, platelet-free
plasma; PPP, platelet-poor plasma; PRP, platelet-rich plasma.
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OPEN ACCESSorgans that actively shed RNA (at the gestational age of sampling)
into the amniotic cavity. These data strongly suggest that biofluid
mRNA levels, at least to some degree, reflect intracellular mRNA
levels from cells that produce or transport the fluid. To further
investigate the origin of biofluid RNA at the cellular level, we
applied computational deconvolution of the pancreatic cyst fluid
RNA profiles using single-cell RNA-sequencing data from 10
pancreatic cell types (Baron et al., 2016). Figure 5B reveals that
pancreatic cyst fluid 1 consists of 45% activated stellate cells
and 43% endothelial cells, while pancreatic cyst fluid 2 mainly
consists of quiescent stellate cells (38%), endothelial cells
(31%), and acinar cells (19%).
Biomarker Potential ofmRNA inSputum,Urine,CSF, and
Saliva in Selected Case/Control Cohorts
Additional biofluid samples were collected in patients with a spe-
cific disease or in healthy controls to investigate potential biolog-ically relevant differences in mRNA content between both
groups. Sequin RNA spikes were used for biofluid volume-based
data normalization. Strikingly, the relative RNA concentration in
sputum of COPD patients was higher than in non-COPD pa-
tients, probably reflecting the high turnover of immune cells dur-
ing the state of chronic inflammation (Figure 6A). Differential
expression analysis revealed 5,513 and 6 mRNAs that were
significantly up- and downregulated, respectively, in sputum
fromCOPD patients compared to that from healthy controls (Fig-
ure 6B). CCL20, the most differential mRNA, showed a 146-fold
upregulation in COPD patients compared to that in healthy do-
nors. This potent chemokine attracting dendritic cells has previ-
ously been linked to the pathogenesis of COPD (Bracke et al.,
2006; Demedts et al., 2007); ADA and MMP1, also among
the most differential mRNAs, have also been associated with
the pathogenesis of COPD (Karmouty-Quintana et al., 2013;
Singh Patidar et al., 2018; Stankovic et al., 2017). To verify theCell Reports 33, 108552, December 29, 2020 7
A
B
Figure 4. Reads Mapping to Bacterial Ge-
nomes
(A) Percentage of reads mapping to bacteria in
mRNA data (pink) and in small-RNA-sequencing
data (blue).
(B) Percentage of reads mapping to Campylo-
bacter concisus in mRNA data (pink) and in small-
RNA-sequencing data (blue). Campylobacter
concisus is known to be present in saliva.
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OPEN ACCESSRNA-sequencing findings, 8/8 of themost differentially abundant
mRNAs were validated by qRT-PCR (Figures S11A and S11B).
In contrast to that in patients with COPD, the relative RNA con-
tent is comparable in urine from bladder cancer patients and
healthy volunteers, in CSF from glioblastoma patients and hy-
drocephalus patients, and in saliva from diabetes patients and
healthy volunteers (Figures 6C–6E and S12). A higher RNA yield
in CSF from glioblastoma patients compared to that in CSF from
healthy controls has been reported by Saugstad et al. (2017);
however, the collection method of CSF differed between both
groups, and it is therefore not possible to assess whether the re-
ported difference in RNA yield between both groups is due to the
different CSF collection sites (lumbar puncture versus crani-
otomy) or due to the neurological disease. In urine from patients
with a muscle-invaded bladder cancer, 529 mRNAs and 9
mRNAs were significantly upregulated and downregulated,8 Cell Reports 33, 108552, December 29, 2020respectively, compared to urine from
healthy volunteers (Figure 6D). Some of
the upregulated mRNAs, such as MDK,
SLC2A1, GPRC5A, KRT17, and KRT5,
have been reported in urine and were
suggested as biomarkers for the accurate
detection and classification of bladder
cancer (Eckstein et al., 2018; Holyoake
et al., 2008; Lin et al., 2019; Murakami
et al., 2018). In CSF from glioblastoma
patients, only 2 mRNAs are significantly
upregulated compared to that in CSF
from hydrocephalus patients. CD163,
one of the upregulated genes in glioblas-
toma, has been linked with glioblastoma
pathogenesis (Chen et al., 2019). In saliva
from diabetes patients and saliva from
healthy volunteers, no differentially ex-
pressed genes could be identified.
Differential abundance analysis was
performed for circRNAs as well, but in
none of the case/control cohorts could
differentially abundant circRNAs be de-
tected (data not shown). As circRNAs
can only be identified based on their
backsplice junction, the read coverage
is generally (too) low for biomarker dis-
covery based on mRNA-capture-
sequencing data.When applying a similar
strategy for mRNAs by looking at the
reads of only one ‘‘linear-only’’ junctionper gene (outside every detected backsplice junction) a signifi-
cantly lower number of differentially abundant mRNAs was de-
tected (sputum: 13 out of 5,519 mRNAs; urine: 0 out of 538
mRNAs; CSF: 0 out of 35 mRNAs). These results strongly sug-
gest that a dedicated circRNA enrichment strategy may be
needed to assess circRNA biomarker potential.
To validate the identification of the 10 most abundant circR-
NAs detected by mRNA capture sequencing in sputum, an
orthogonal validation by qRT-PCR of the backsplice sequence
region was performed. For 9 of the 10 circRNAs, the RNA-
sequencing results could be validated (Figure S11C).
DISCUSSION
By applying two complementary RNA-sequencing technologies
on 20 different biofluids, we assembled themost comprehensive
A B
Figure 5. Identification of the Tissues of Origin per Biofluid and Deconvolution of Pancreatic Cyst Fluid
(A) Assessment of the tissues of origin in the biofluids of the discovery cohort.
(B) Heatmap showing tissues and cell types that contribute more specifically to a certain biofluid compared to the other biofluids. Rows depict the biofluids of the
discovery cohort, and the columns indicate the tissues or cell types for which markers were selected based on the RNA Atlas (Lorenzi et al., 2019). For visu-
alization purposes, only tissues and cell types with a Z-score-transformed log2 fold change R |1| in at least one biofluid are indicated.
(C) Composition of pancreatic cyst fluid samples based on deconvolution using sequencing data from 10 pancreatic cell types.
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OPEN ACCESShuman biofluid transcriptome, covering small RNAs, mRNAs and
circRNAs. Until now, most efforts to investigate and compare the
RNA content within biofluids focused on small RNA sequencing,
most likely because of technical limitations and unawareness of
the abundance of extracellular mRNA (fragments) (El-Mogy
et al., 2018; Ferrero et al., 2017; Godoy et al., 2018; Srinivasan
et al., 2019; Weber, 2017; Yeri et al., 2017).
The availability of both small RNA-sequencing data andmRNA
data allows a more in-depth characterization of the human tran-
scriptome in biofluids. To our knowledge, this is the first study re-
porting on the mRNA content, generated through a dedicated
mRNA enrichment-sequencing method, in tear fluid, amniotic
fluid, aqueous humor, bile, bronchial lavage fluid, gastric fluid,
saliva, seminal plasma, synovial fluid, sweat, and urine. Selected
mRNAs were previously studied by means of qRT-PCR in amni-
otic fluid (Welch et al., 2016), pancreatic cyst fluid (Maker et al.,
2019; Marzioni et al., 2015), seminal plasma (Tian et al., 2016),
sputum (Oreo et al., 2014), stool (Herring et al., 2018), and in
extracellular vesicles isolated from cell-free urine (Bazzell et al.,
2018). In saliva, selected mRNAs were detected using microar-
rays (Zhang et al., 2010). We have demonstrated that it is techni-
cally feasible to generate mRNA data from low-input biofluid
samples. This is expected to accelerate biomarker research in
these fluids. Further efforts to profile and share the mRNA and
circRNA content in larger sample cohorts of biofluids, compara-
ble to the exRNA Atlas Resource for small RNAs, are necessary
to move this scientific field forward (Murillo et al., 2019).Synthetic spike-in controls allowed for a direct comparison of
RNA content across biofluids, revealing a 10,000-fold difference
in concentration. Of note, the RNA concentration is not perfectly
correlated with the transcriptome complexity (as reflected by the
number of miRNAs and the number of mRNAs detected per
sample; Table 1).
Our small RNA results confirm previous studies observing a
highmiRNA concentration in tears (Weber et al., 2010), lowmap-
ping rates in CSF (Godoy et al., 2018; Waller et al., 2018), and a
lowmiRNA concentration in cell-free urine (El-Mogy et al., 2018).
A direct comparison of the absolute numbers of detected miR-
NAs, mRNAs, and circRNAs detected per sample in our study
with the numbers in published literature is hampered by the
fact that the absolute read count is dependent on the input vol-
ume of the biofluids, the RNA isolation kit, and library preparation
method used, the sequencing depth, and data-analysis settings
(e.g., mapping without mismatches and filtering of the data). In
addition, different pre-analytical variables when preparing the
biofluid samples may also affect the sequencing results. Howev-
er, on a higher level, we can look into themost abundant miRNAs
detected in specific biofluids. The majority of the 10 most abun-
dant miRNAs detected in 9 specific biofluids reported by Godoy
et al. (2018) are also detected among the most abundant miR-
NAs in the samples from the discovery cohort (Table S1).
We compared the mRNA results of the discovery cohort with
these of the case/control cohorts. Mapping rates for samples







Figure 6. Relative RNA Concentration and Volcano Plot in Case/Control Cohorts
Boxplots of relative mRNA content (top) and volcano plots of differentially expressed mRNAs (bottom) (q < 0.05; pink indicates up, and blue indicates down in
patient versus control) with labeling of up to the 5 most differential genes.
(A) Sputum from COPD patients (n = 8) compared to sputum from healthy donors (n = 8; Wilcoxon rank test, two-sided, p = 7e3).
(B) 5,513 and 6 mRNAs up and down, respectively, in COPD samples.
(C) Urine from bladder cancer patients (n = 12) compared to urine from healthy donors (n = 12; Wilcoxon signed-rank test, two-sided, p = 6.8e2).
(D) 529 and 9 mRNAs up and down, respectively, in bladder cancer samples.
(E) CSF from glioblastoma cancer patients (n = 12) compared to CSF from hydrocephalus patients (n = 12; Wilcoxon signed-rank test, two-sided, p = 7.1e1).
(F) 2 and 33 mRNAs up and down, respectively, in glioblastoma samples.
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OPEN ACCESSand seminal plasma. The mapping rates for CSF and urine are
about 15%higher in the case/control cohorts compared to those
in the discovery cohort. These differences may be due to
different pre-analytical variables between both cohorts (collec-
tion tube, centrifugation speed, and the portion of urine
collected) (Figure S4A;Methods S1). Note that sputum in the dis-
covery cohort was collected as spit samples from volunteers
with a common cold, while all 16 sputum samples of the case/
control cohort were collected through sputum induction.
In the discovery cohort, on average, 53% of all small RNA
reads in saliva can be traced to bacteria, perfectly in line with
the average of 45.5% reads mapping to bacteria reported by
Yeri et al. (2017). Aqueous humor and CSF, although collected
in a sterile setting and presumed to be sterile, contain up to
11% of reads mapping to bacteria, in line with previous studies
(Godoy et al., 2018; Waller et al., 2018). However, bacterial cul-10 Cell Reports 33, 108552, December 29, 2020tures of our two CSF samples were negative. As both CSF and
aqueous humor display a very low relative RNA content, the
exogenous sequences may represent bacterial contaminants
introduced during the sample processing workflow. Contami-
nants can derive from contaminated spin columns used during
RNA purification (Heintz-Buschart et al., 2018), enzymes pro-
duced in microorganisms (Salter et al., 2014), or various environ-
mental sources (Strong et al., 2014). Such contaminant signals
are likely underrepresented in samples with a high concentration
of endogenous exRNAs. The exogenous RNA content was as-
sessed in both the mRNA-capture-sequencing data and the
small-RNA-sequencing data. As the mRNA capture probes
were not designed to capture exogenous RNA, mRNA capture
sequencing is not the preferred method for bacterial RNA quan-
tification. Despite the shortcomings of the capture technique, the
abundance estimates of the bacterial species derived from the
Resource
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OPEN ACCESSmRNA capture data match with those derived from the small-
RNA-sequencing data (the latter being unbiased with respect
to bacterial RNA quantification).
Although we collected a broad range of biofluids, only two
samples per biofluid were studied, limiting our ability to assess
donor variability. The input volume for the RNA isolations in all
biofluids was set to 200 mL, and a volume-based comparison
of the RNA content was made among the biofluids. We did not
explore whether higher input volumes would result in higher
RNA yields in biofluids where this could have been possible
(e.g., urine). We also note that the results in Table 1 are impacted
by biofluid input volume in the RNA purification, RNA input in the
sequencing library preparation, and the sequencing depth.
Biofluid data normalization with synthetic spike-in controls is a
unique and powerful approach and reflects more accurately the
biological situation compared to classic normalization ap-
proaches where global differences on overall abundance are
neutralized. For instance, the relative mRNA concentration in
sputum from COPD patients is higher than in sputum from
healthy donors. Typically, RNA-sequencing data are sub-
sampled or normalized based on the library size before perform-
ing a differential expression analysis, resulting in an artificially
more balanced volcano plot, an overcorrection of the biological
situation, and a loss of information, which is not the case when
the data are normalized based on spike-in controls.
Our results highlighting tissues and cell types that contribute
more specifically to a certain biofluid compared to the other bio-
fluids (Figure 5A) can be used as a roadmap to formulate hypoth-
eses when initiating biomarker research. Not surprisingly, the
RNA signal from prostate is reflected in urine and seminal
plasma. Both fluids can be collected in a non-invasive way and
may be of value to investigate further in prostate cancer patients.
Of interest, the mRNA concentration in seminal plasma is 1,000-
fold higher than in urine, and seminal plasma contains more
unique mRNAs compared to urine, suggesting that the
biomarker potential of seminal plasma is higher. However, one
should also be cautious in interpreting the tissue enrichment re-
sults: although the RNA signal of breast seems relatively en-
riched in sweat, this biofluid has the lowest RNA concentration.
The limited number of detected mRNAs in sweat show overlap
with mRNAs related to secretion (MCL1 gene, SCGB2A2 gene,
and SCGB1D2 gene) that also appear as markers in breast
tissue.
The pancreatic tissue RNA signal appears to be enriched in
pancreatic cyst fluid, and a different cell-type composition is
observed when both samples are deconvoluted using single-
cell RNA-sequencing data of pancreatic cell types (Figure 5B).
Pancreatic cyst fluid was collected in these donors to investigate
a cystic lesion in the pancreas. The routine cytological analysis of
these fluid samples was inconclusive at the moment of sample
collection. By following up both patients, we discovered that
the first patient developed a walled-off necrosis collection after
necrotizing pancreatitis. The incipient high fraction of activated
stellate cells in the first cyst fluid sample may have been an indi-
cation pointing toward the inflammation and necrosis that finally
occurred. The second patient was diagnosed with a side-branch
intra-papillary mucinous neoplasia, probably reflected by the
relative high fraction of acinar cells. Pancreatic cysts are oftendetected on abdominal imaging, resulting in a diagnostic and
treatment dilemma. Furthermore, pancreatic cysts represent a
broad group of lesions, ranging from benign to malignant en-
tities. The main challenge in their management is to accurately
predict the malignant potential and to determine the risk to
benefit of a surgical resection (Farrell, 2017). Our results show
that the cellular contribution to the RNA content of pancreatic
cyst fluids can be estimated through deconvolution and that
these results may be associated with clinical phenotypes. Larger
cohorts are necessary to investigate the clinical potential of this
approach, and pancreatic tumor cells may also need to be
added to the reference set with single-cell RNA-sequencing
data to improve the accuracy of the prediction.
In addition to linear mRNA transcripts, we also explored the
circRNA content in biofluids. circRNAs are a growing class of
non-coding RNAs and a promising RNA biotype to investigate
in the liquid biopsy setting, as they are presumed to be less
prone to degradation compared to linear forms (Jeck and Sharp-
less, 2014). circRNAs can be detected with mRNA capture
sequencing through the capture of exons that are incorporated
in the circRNAs, followed by identification of the characteristic
backsplice junction. The circRNA fraction in tissues has previ-
ously been reported and is in line with our findings (Guo et al.,
2014). In our study, we demonstrated that, for genes that pro-
duce both circRNAs and linear mRNAs, the circRNAs are more
abundant than the linear forms in biofluids. Further assessment
of the biomarker potential of circRNAs in biofluids require dedi-
cated library preparation methods with circRNA enrichment.
In conclusion, The Human Biofluid RNA Atlas provides a sys-
tematic and comprehensive comparison of the exRNA content in
20 different human biofluids. The results presented here may
serve as a valuable resource for future biomarker studies.STAR+METHODS
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Data and Code Availability
The raw RNA-sequencing data have been deposited at the European Genome-phenome Archive (EGA):EGAS00001003917. The
small RNA sequencing data was deposited in the exRNA Atlas portal (https://exrna-atlas.org). All spike-normalized sequencing
data can be readily explored in the interactive web-based application R2: Genomics analysis and visualization platform (http://r2.
amc.nl), and via a dedicated accessible portal (http://r2platform.com/HumanBiofluidRNAAtlas). This portal allows the analysis
and visualization of mRNA, circRNA andmiRNA abundance, as illustrated in Figure S13. All samples can be used for correlation, prin-
ciple component, and gene set enrichment analyses, andmany more. All other data are available within the article and Supplemental
Information. The R scripts to reproduce the analyses and plots reported in this paper are available from the corresponding authors
upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Donor material, collection and biofluid preparation procedure
Sample collection for the discovery cohort and sputum collection for the case/control cohort was approved by the ethics committee
of Ghent University Hospital, Ghent, Belgium (no. B670201734450) and written informed consent was obtained from all donors ac-
cording to the Helsinki declaration. Breast milk, colostrum, plasma, serum, sputum, seminal plasma, sweat, stool, tears and urine
were obtained in healthy volunteers. All other biofluids were collected from non-oncological patients.
The collection of two case series of each 12 cases and 12 control samples was approved by the Masaryk Memorial Cancer Insti-
tute, Brno, Czech Republic (no. 14-08-27-01 and no. MOU190814). Urine was collected in healthy donors and muscle-invasive
bladder cancer patients; CSF was collected in hydrocephalus patients and glioblastoma patients.
Collection of saliva samples in 12 healthy donors and in patients with diabetesmellitus for the case/control cohort was approved by
the ethics committee of the Medical University of Vienna, Vienna, Austria (no. 2197/2015). Written informed consent was obtained
from all donors. The demographic and clinical patient information is provided in Table S1. Detailed information on the sample collec-
tion per biofluid is provided in Methods S1. All samples, except tear fluid, plasma and serum, were centrifuged at 2000 g (rcf.) for
10 minutes without brake at room temperature. All samples were processed within 2 hours after collection. The cell-free supernatant
was carefully pipetted into 2 mL LoBind tubes (Eppendorf LoBind microcentrifuge tubes, Z666556-250EA) and stored at 80C.
METHOD DETAILS
RNA isolation and gDNA removal
RNA isolation from all biofluids, except tears
In the discovery cohort, two RNA isolations per biofluid and per sample were simultaneously performed by two researchers (E.V.E.
and E.H.). In the end, RNA obtained from both RNA isolations was pooled per biofluid and per sample and this pooled RNA was used
as starting material for both library preparations. Hence, small RNA and mRNA capture sequencing on the discovery cohort were
performed on the same batch of RNA. In the case/control cohorts, one RNA isolation was performed per sample and the RNA
was used as starting material for mRNA capture sequencing.
RNA was isolated with the miRNeasy Serum/Plasma Kit (QIAGEN, Hilden, Germany, 217184) according to the manufacturer’s in-
structions. An input volume of 200 mL was used for all samples, except for tear fluid, and total RNA was eluted in 12 mL of RNase-free
water. Tear fluid was collected with Schirmer strips and RNA was isolated directly from the strips (see further). Per 200 mL biofluid
input volume, 2 mL Sequin spike-in controls (Garvan Institute of Medical Research) and 2 ml RNA extraction Control (RC) spike-ins
(Integrated DNA Technologies) (Locati et al., 2015) were added to the lysate for TruSeq RNA Exome Library Prep sequencing and
TruSeq Small RNA Library Prep sequencing, respectively. Details on the spike-in controls are available in the Methods S1.
Briefly, 2 ml External RNAControl Consortium (ERCC) spike-in controls (ThermoFisher Scientific,Waltham,MA, USA, 4456740), 2 ml
Library Prep Control (LP) spike-ins (Integrated DNA Technologies) (Hafner et al., 2011), 1 ml HL-dsDNase and 1.6 ml reaction buffer
were added to 12 ml RNA eluate, and incubated for 10min at 37C, followed by 5min at 55C. Per biofluid and per donor the RNA after
gDNA removal was pooled. RNAwas stored at80Cand only thawed on ice immediately before the start of the library prep.Multiple
freeze/thaw cycles did not occur.
RNA isolation from tear fluid
Tear fluid was collected in 8 healthy donors with Schirmer strips (2 strips per eye per donor), as previously described (Green-Church
et al., 2008; Pieragostino et al., 2017). RNA was isolated within two hours after tear collection with the miRNeasy Serum/Plasma Kit
(QIAGEN,Hilden, Germany, 217184), starting fromone 2mL tube containing each 4 Schirmer strips. The same reagent volumes as sug-
gested by the manufacturer for a 200 mL input volume were used. Throughout the RNA isolation protocol, the two final RNA samples
each result from 4 tear fluid samples (each containing the 4 strips of a single donor) that were pooled in a two-step method. First, the
upper aqueous phase of two tear fluid samples was put together (in step 8 of the RNA isolation protocol). Second, the RNA eluate of
these two samples was pooled into the final RNA that was used as input for the library prep (in step 15 of the RNA isolation protocol).e2 Cell Reports 33, 108552, December 29, 2020
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Messenger RNA capture based libraries were prepared starting from 8.5 mL DNase treated and spike-in supplemented RNA eluate
using the TruSeq RNA Exome Library Prep Kit (Illumina, San Diego, CA, USA). Each sample underwent individual enrichment accord-
ing to the manufacturer’s protocol. The quality and yield of the prepared libraries were assessed using a high sensitivity Small DNA
Fragment Analysis Kit (Agilent Technologies, Santa Clara, CA, USA) according to manufacturer’s instructions. The libraries were
quantified using qPCR with the KAPA Library Quantification Kit (Roche Diagnostics, Diegem, Belgium, KK4854) according to man-
ufacturer’s instructions. Based on the qPCR results, equimolar library pools were prepared.
Paired-end sequencing was performed on a NextSeq 500 instrument using a high output v2 kit (Illumina, San Diego, CA, USA) with
a read length of 75 nucleotides to an average sequencing depth of 11million read pairs in the discovery cohort, 16.8million read pairs
in the sputum case/control cohorts, 15.4million read pairs in the urine case/control cohort, 15million read pairs in the CSF case/con-
trol cohort and 18.8 million read pairs in the saliva case/control cohort. Samples from the discovery cohort were randomly assigned
over two pools and sequenced with a loading concentration of 1.2 pM (5%PhiX) and 1.6 pM (5% PhiX), respectively. Urine, CSF and
saliva samples from the case/control cohorts were loaded in 3 separate runs at 2 pM (2% PhiX) and sputum samples from the case/
control cohorts were loaded at 1.6 pM (5% PhiX).
TruSeq Small RNA library prep sequencing
Small RNA libraries were prepared starting from 5 mL DNase treated and spike-in supplemented RNA eluate using a TruSeq Small
RNA Library Prep Kit (Illumina, San Diego, CA, USA) according to the manufacturer’s protocol with two minor modifications(1). The
RNA 30 adaptor (RA3) and the RNA 50 adaptor (RA5) were 4-fold diluted with RNase-free water(2) and the number of PCR cycles was
increased to 16.
First, a volume-based pool of all 46 samples of the discovery cohort was sequenced. After PCR amplification, quality of libraries was
assessed using a high sensitivity Small DNA Fragment Analysis Kit (Agilent Technologies, Santa Clara, CA, USA) according to manu-
facturer’s instructions. Size selection of the pooled samples was performed using 3%agarose dye-freemarker H cassettes on a Pippin
Prep (Sage Science, Beverly, MA, USA) following manufacturer’s instructions with a specified collection size range of 125–163 bp. Li-
braries were further purified and concentrated by ethanol precipitation, resuspended in 10 ml of 10mM tris-HCl (pH = 8.5) and quantified
using qPCR with the KAPA Library Quantification Kit (Roche Diagnostics, Diegem, Belgium, KK4854) according to manufacturer’s in-
structions. The pooled library was quality controlled via sequencing at a concentration of 1.7 pMwith 35%PhiX on a NextSeq 500 using
a mid-output v2 kit (single-end 75 nucleotides, Illumina, San Diego, CA, USA), resulting in an average sequencing depth of 1 million
reads, ranging from 3341 reads to 14million reads. Twenty-three samples with less than 200 000 reads were assigned to a low concen-
trated pool, 23 samples with more than 17million reads were assigned to a highly concentrated pool. Based on the read numbers from
the mid output run, two new equimolar pools were prepared, purified and quantified as described higher. Both re-pooled libraries were
then sequenced at a final concentration of 1.7 pM with 25% PhiX on a NextSeq 500 using a high output v2 kit (single-end, 75 nucleo-
tides, Illumina, San Diego, CA, USA), resulting in an average sequencing depth of 9 million reads (range 817 469 – 41.7 million reads).
RT-qPCR
To validate findings observed in the RNA sequencing data, we performed a targetedmRNAand circRNA expression profilingwith RT-
qPCR for 8 differentially expressed mRNAs in sputum (COPD versus healthy control) and for the 10 most abundant circRNAs in
sputum. As reference RNAs for normalization purposes, we selected Sequin spikes stably detected in all samples based on the avail-
able RNA sequencing data. The assays to measure mRNA, circRNA and Sequin spike expression were custom designed using pri-
merXL (Lefever et al., 2017) (Table S1) and purchased from Integrated DNA Technologies, Inc. (Coralville, USA).
For cDNA synthesis, 5 mL of total RNAwas reverse transcribed using the iScript Advanced cDNA Synthesis Kit (BioRad, USA, 172-
5038) in a 10 mL volume. 5 mL of cDNA was pre-amplified in a 12-cycle PCR reaction using the SsoAdvanced PreAmp Supermix (Bio-
Rad, USA, 172-5160) in a 50 mL reaction. Pre-amplified cDNA was diluted (1:8) and 2 mL was used as input for a 45-cycle qPCR
reaction, quantifying 8 mRNAs and 10 circRNAs of interest with the SsoAdvanced Universal SYBR Green Supermix (BioRad,
USA, 172-5275). All reactions were performed in 384-well plates on the LightCycler480 instrument (Roche) in a 5 mL reaction volume
using 250 nM primer concentrations. Cq-values were determined with the LightCycler480 Software (release 1.5.0, Roche) with the
‘‘Abs Quant/2nd Derivative Max’’ method.
The geNorm analysis to select the optimal number of reference targets was performed using Biogazelle’s qbase+ software (www.
qbaseplus.com) using log2-transformed RNA count data. We observed medium reference target stability (average geNormM% 1.0)
with an optimal number of reference targets in this experimental situation of two (geNorm V < 0.15 when comparing a normalization
factor based on the two or three most stable targets). As such, the optimal normalization factor can be calculated as the geometric
mean of reference targets R2_150 and R2_65. These Sequin spike RNAs were considered as reference RNAs.
QUANTIFICATION AND STATISTICAL ANALYSIS
Processing TruSeq RNA Exome sequencing data
Read quality was assessed by running FastQC (v0.11.5) on the FASTQ files and reads shorter than 35 nucleotides and with a quality
(phred) score < 30 were removed. The reads were mapped with STAR (v2.6.0). Mapped reads were annotated by matching genomicCell Reports 33, 108552, December 29, 2020 e3
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OPEN ACCESScoordinates of each read with genomic locations of mRNAs (obtained from UCSC GRCh38/hg38 and Ensembl, v91) or by matching
the spike-in sequences. Picard (v2.18.5) was used for duplicate removal. HTSeq (v0.9.1) was used for quantification of PCR dedu-
plicated reads. A cut-off for filtering noisy genes was set based on historic data to remove noisy genes. Using a threshold of 4 counts,
at least 95% of the single positive replicate values are filtered out. A table with the read count of mRNAs per sample is provided in
Table S1.
Processing TruSeq Small RNA sequencing data
Adaptor trimming was performed using Cutadapt (v1.8.1) with a maximum error rate of 0.15. Reads shorter than 15 nts and those in
which no adaptor was foundwere discarded. For quality control the FASTX-Toolkit (v0.0.14) was used, aminimumquality score of 20
in at least 80% of nucleotides was applied as a cutoff. The reads were mapped with Bowtie (v1.1.2) without allowing mismatches.
Mapped reads were annotated by matching genomic coordinates of each read with genomic locations of miRNAs (obtained from
miRBase, v22) and other small RNAs (obtained fromUCSCGRCh38/hg38 and Ensembl, v91) or bymatching the spike-in sequences.
Reads that map tomore than one small RNA biotype are considered as ‘‘multimapped.’’ Only reads that uniquelymap to one biotype,
are included in the different small RNA biotype categories in Figure 2. Reads assigned as ‘‘not annotated’’ represent mapped reads
that could not be attributed to small RNA biotype groups. The mapping locations of the uniquely mapped not annotated reads were
cross-matched with all exonic, intronic and intergenic positions in the Ensembl reference transcriptome (obtained from UCSC
GRCh38/hg38 and Ensembl, v91) using the intersect feature in bedtools (requiring an overlap of 100% between the not annotated
read and the position of the Ensembl reference transcriptome). As for the mRNA data, genes with fewer than 4 counts were filtered
out. A table with the read count of miRNAs per sample is provided in Table S1.
Calculation of endogenous RNA concentration
A biofluid volume-based normalization was applied by dividing the number of RNA reads consumed by the endogenous transcripts
by the sum of the Sequin reads for mRNA data and by the sum of the RC reads for small RNA data. The spike-normalized data repre-
sent relative abundance values of RNA molecules proportional to the input volume.
The mass of endogenous mRNA present in 1 mL of each biofluid was estimated based on the read count for ERCC-00130 spike-in
RNA, detected in all biofluids with at least 4 counts. The RNA eluate of each sample contains 6E-20mol of ERCC-00130, which has a
molecular weight of 340415.55 g/mol. Based on the read count for the endogenous mRNA, the corresponding mass of endogenous
mRNA in the eluate was calculated and corrected for input volume.
Exogenous RNA characterization
The exogenous RNA content in the mRNA data was assessed using the MetaMap pipeline (Simon et al., 2018). Briefly, all reads were
mapped to the human reference genome (hg38) using STAR (v2.5.2) (Dobin et al., 2013). Unmapped reads were subsequently sub-
jected to metagenomic classification using CLARK-S (v1.2.3) (Ounit and Lonardi, 2016). Reads were summed across all bacterial
species.
The exogenous RNA content in the small RNA data was assessed using the exceRpt small RNA-seq pipeline (v4.6.2) in the Gen-
boree workbenchwith default settings (Rozowsky et al., 2019). Briefly, after adaptor trimming, read quality was assessed by FASTQC
(v0.11.2). A minimum quality score of 20 in at least 80% of nucleotides was applied as cutoff. The minimum read length after adaptor
trimming was set to 18 nucleotides. Reads were first mapped to the custom spike-in sequences using Bowtie2 (v2.2.6), followed by
mapping the unmapped reads with STAR (v2.4.2a) to UniVec contaminants and human ribosomal (rRNA) sequences to exclude them
before mapping (also with STAR) to the following databases: miRbase (v21), gtRNAdb, piRNABank, GeneCode version 24 (hg38) and
circBase (version last updated in July 2017). A singlemismatchwas allowed duringmapping to the human genome. Unmapped reads
were then mapped with STAR to exogenous miRNAs and rRNAs. In the end, the remaining unmapped reads were mapped to the
genomes of all sequenced species in Ensembl and NCBI. No mismatches were allowed during exogenous alignment. Raw read
counts obtained from the Genboree workbench were further analyzed in R (v3.5.1) making use of tidyverse (v1.2.1).
Circular RNA detection and circular/linear ratio determination
Only TruSeq RNA Exome reads passing quality control (base calling accuracy of R 99% in at least 80% of the nucleotides in both
mates of a pair) were included in this analysis. Clumpify dedupe (v38.26) was used to remove duplicates in paired-end mode (2 al-
lowed substitutions, kmer size of 31 and 20 passes). We used a two-step mapping strategy to identify forward splice (further referred
to as linear) junction reads and backsplice junction reads. First, reads were aligned with TopHat2 (v2.1.0) to the GRCh38/hg38 refer-
ence genome (Ensembl, v91) (Kim et al., 2013). Micro-exons were included, a minimum anchor length of 6 nucleotides was required,
and up to two mismatches in the anchor region were allowed. The resulting output contains linear junction information. Second, un-
mapped reads from the first mapping strategy were realigned with TopHat2 (v2.1.0) to the same reference, but this time with the
fusion search option that can align reads to potential fusion transcripts. Processing the fusion search output with CIRCexplorer2
parse (v2.3.3) results in backsplice junction information (Zhang et al., 2016). Junction read counts obtained with the mapping stra-
tegies described above were used as a measure for the relative level of linear and circular RNA in each sample. Only genes with at
least one detected backsplice junction were considered. Junctions that could be part of both linear and circular transcripts (ambig-
uous junctions) were filtered out. As there is currently no consensus on how to calculate the circular to linear ratio (CIRC/LIN), wee4 Cell Reports 33, 108552, December 29, 2020
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method (referred to as ‘‘backsplice junction-level method’’) zooms in on each particular backsplice junction. CIRC was defined as
the backsplice junction read count of one particular backsplice junction. LIN was defined as the average read count of all junctions
flanking the backsplice junction of interest. The second method (referred to as ‘‘gene-level method’’) considers all backsplice junc-
tions within a given gene. CIRCwas defined as the average number of backsplice junction reads for a given gene. LIN was defined as
the average number of linear junction reads for a given gene. For both methods, CIRC > 3 was used as a cut-off for filtering noisy
backsplice junctions. To enable a comparison of the circular/linear genic ratios in biofluids with those of tissues, the mRNA capture
sequencing FASTQ files of 16 cancerous tissue types (34 samples in total) were downloaded from theMiOncoCirc database (dbGaP
Study Accession phs000673.v3.p1) (Vo et al., 2019). A list with the downloaded samples is attached in Table S1. A table with the read
count of backsplice junctions per sample is provided in Table S1.
Assessment of tissue and cell contribution to biofluid exRNA
Using total RNA-sequencing data from 27 normal human tissue types and 5 immune cell types from peripheral blood from the RNA
Atlas (Lorenzi et al., 2019), we created gene sets containing marker genes for each individual entity (Table S1). We removed redun-
dant tissues and cell types from the original RNA Atlas (e.g., granulocytes and monocytes were present twice; brain was kept and
specific brain sub-regions such as cerebellum, frontal cortex, occipital cortex and parietal cortex were removed) and we used genes
where at least one tissue or cell type had expression values greater or equal to 1 TPM normalized counts. A gene was considered to
be a marker if its abundance was at least 5 times higher in the most abundant sample compared to the others. For the final analysis,
only tissues and cell types with at least 3 markers were included, resulting in 26 tissues and 5 immune cell types.
Gene abundance read counts from the biofluids were normalized using Sequin spikes as size factors in DESeq2 (v1.22.2). For all
marker genes within each gene set, we computed the log2 fold changes between the median read count of a biofluid sample pair
versus the median read count of all other biofluids. The median log2 fold change of all markers in a gene set was selected, followed
by z-score transformation over all biofluids (Figure 6). For visualization purposes, only tissues and cell types with a z-scoreR |1| in at
least one biofluid were used.
Cellular deconvolution of pancreatic cyst fluid samples
To build the reference matrix for the computational deconvolution of pancreatic cyst fluid samples, single cell RNA sequencing data
of 10 pancreatic cell types (Baron et al., 2016) was processedwith the statistical programming languageR (v3.6.0). For each gene, the
mean count across all individual cells from each cell type was computed. Next, this reference matrix was normalized using the
trimmed means of M values (TMM) with the edgeR package (v3.26.4)(Robinson et al., 2010). Limma-voom (v3.40.2) (Ritchie et al.,
2015) was used for subsequent differential gene expression analysis and those genes with an absolute fold change greater or equal
to 2 and an adjusted p value < 0.05 (Benjamini-Hochberg) were retained as markers (Benjamini and Hochberg, 1995). Finally, using
these markers and both the pancreatic cyst fluid samples and the reference matrix described above, the cell type proportions were
obtained through computational deconvolution using non-negative least-squares (nnls package; v1.4) (Avila Cobos et al., 2018;
Mullen and van Stokkum, 2012).
Differential expression analysis in case/control cohorts
Further processing of the count tables was done with R (v3.5.1) making use of tidyverse (v1.2.1). Gene abundance expression read
counts from the biofluids were normalized using the sum of all reads mapping to Sequin spikes as size factors in DESeq2 (v1.20.0)
(Love et al., 2014). To assess the biological signal in the case/control cohorts, we performed differential expression analysis
between the patients and control groups using DESeq2 (v1.20.0). Genes were considered differentially expressed when the ab-
solute log2 fold change > 1 and at q < 0.05. A list with differentially expressed genes in all case/control cohorts can be found in
Table S1.Cell Reports 33, 108552, December 29, 2020 e5
